BURZYNSKI RESEARCH INSTITUTE INC (BZYR)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-12

Key Insights

The company is unable to fund SEC reporting compliance costs and expects to miss its Annual Report 10-K filing deadline of May 29, 2026, indicating severe financial distress and operational challenges.
Dr. Stanislaw Burzynski, who has historically funded company operations and owns the majority of shares, has stated he lacks available resources to continue funding SEC compliance costs, suggesting a critical funding crisis.
Delinquency in SEC filings could trigger trading suspensions under Section 12(k) or revocation of securities registration under Section 12(j), which would severely restrict or eliminate trading liquidity and investor ability to transact in the stock.
The company's ability to remain a publicly traded entity is at immediate risk, as failure to file required periodic reports could result in loss of Exchange Act registration and broker-dealer restrictions on quotations.

Current Report Filed: 2026-04-23

Key Insights

CFO departure: Patryk P. Goscianski resigned as CFO and Secretary effective April 17, 2026, with no stated disagreements regarding company operations, suggesting an amicable transition.
Consolidation of leadership: Dr. Stanislaw R. Burzynski (age 83), the controlling stockholder and President/Chairman, assumed the dual role of CFO and principal financial officer without additional compensation, which raises governance concerns regarding lack of independent financial oversight.
Potential governance risk: The appointment creates a significant concentration of power with one individual serving as President, Chairman, CEO, and CFO, reducing checks and balances typically expected in corporate governance structures.
Related party relationships: Dr. Burzynski maintains multiple material agreements with the company (New License Agreement, Amended and Restated Research Funding Agreement, and Royalty Agreement) that now require enhanced scrutiny given his expanded financial control.

Quarterly Report Filed: 2026-01-13

Key Insights

The company's retained earnings and additional paid-in capital have been steadily increasing over the past few years, indicating potential financial stability and growth.
The majority shareholder and president has entered into various licensing agreements and research and development arrangements, which could provide additional revenue streams and growth opportunities.
The company has received funding for clinical trials, research, and operational support from related parties, potentially helping to finance its ongoing operations and development efforts.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.